Alkermes: FY2025 revenue $1.48B, GAAP EPS $1.43; 2026 guidance shows net loss from Avadel deal

Alkermes plc.

2025-FY EPS reported $1.43 vs consensus $0.35 ▲ beat (+309.5%)

Total revenue $1.48B in 2025; proprietary net sales up ~9% to $1.18B; LYBALVI grew 22% in Q4.
GAAP net income $242M ($1.43 dil EPS) vs $367M in 2024; Q4 net income $49.3M.
Closed Avadel acquisition Feb 12, 2026; used $775M cash + $1.525B term loans; expects ~$150M inventory step-up expense.
2026 guidance: revenue $1.73-1.84B, GAAP net loss $(115)-$(135)M, adjusted EBITDA $370-410M.
Alixorexton Phase 3 for narcolepsy to start Q1 2026; advancing orexin pipeline for ADHD and fatigue.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.